Search

Author/Creator Mattei, D.

2. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408). (23rd June 2022)

Authors:
Loges, S.; Heuser, M.; Chromik, J.; Sutamtewagul, G.; Kapp-Schwoerer, S.; Crugnola, M.; Di Renzo, N.; Lemoli, R.; Mattei, D.; Ben-Batalla, I.; Waizenegger, J.; Rieckmann, L.-M.; Janning, M.; Imbusch, C. D.; Beumer, N.; Micklem, D.; Gorcea-Carson, C.; Lawson, G.; Nautiyal, J.; Deharo, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS. (23rd June 2022)

Authors:
Bassan, R.; Chiaretti, S.; Della Starza, I.; Spinelli, O.; Santoro, A.; Elia, L.; De Propris, M. S.; Scattolin, A. M.; Paoloni, F.; Messina, M.; Audisio, E.; Marbello, L.; Borlenghi, E.; Zappasodi, P.; Vetro, C.; Martinelli, G.; Mattei, D.; Fracchiolla, N.; Bocchia, M.; De Fabritiis, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search